Bioequivalence Studies Market Size, Share | Report 2022-2030
Industry Insights
The global market for bioequivalence studies is anticipated to register significant growth over the forecast period. The increasing manufacturing of generic drugs and the rising number of clinical trial studies for drug development are the main driving factors of the market, as they help spur the growth of bioequivalence studies, which are performed to form a link between the early and late clinical trial formulations. Furthermore, R&D investments made by various pharmaceutical and biopharmaceutical companies for disease prevention are expected to aid in market growth.
The COVID-19 pandemic has greatly impacted our ability to conduct bioequivalence studies. Due to the pandemic, the government announced a "stay at home" order for the prevention of coronavirus, which led to various clinical trials being halted and delayed, study site closures, laboratory closures, and participant enrollment being postponed. However, bioequivalence studies will resume in the second half of 2020 in order to develop effective drugs for pandemic treatment and prevention.
Based on therapeutic areas , oncology dominated the market. This is because cancer is the main cause of death, making it crucial to guarantee that patients have access to anticancer treatments in order to enhance their quality of life and lower hospital costs and mortality linked to the disease. Bioequivalence studies are thus carried out to investigate these drugs and this helps in the growth of the market. According to WHO, in 2020, cancer accounted for approximately 10 million deaths worldwide.
The North America region is anticipated to dominate the market over the forecast period. This is due to the presence of major market players offering bioequivalence Studies, the expansion of the healthcare infrastructure, and the increasing prevalence of disease, which will increase the demand for drugs that will in turn increase clinical trials for drug development, and the R&D expenditures made by market players for the creation of new treatments and this will help in the growth of bioequivalence studies required to check bioavailability and PK/PD parameters.
The key market players operating in this market are CliniExperts, ICBIO Corporation, ProRelix Services LLP, ICON plc, Charles River Laboratories International, PPD, Inc, Labcorp Drug Development, IQVIA, Syneos Health, SGS SA, and Intertek Group plc. They are adopting various strategies like partnership. collaboration, merger and acquisition, and expansion.
Market Segmentation
By Type Outlook
By Dosage Form Outlook
By Therapeutic Area Outlook
By Phase Outlook
By Regional Outlook
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Bioequivalence Studies Market
5.1. COVID-19 Landscape: Bioequivalence Studies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Bioequivalence Studies Market, By Type
8.1. Bioequivalence Studies Market, by Type, 2022-2030
8.1.1. Small Molecule
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Large Molecule
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Bioequivalence Studies Market, By Dosage Form
9.1. Bioequivalence Studies Market, by Dosage Form, 2022-2030
9.1.1. Solid Oral Dosage
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Parenteral Formulations
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Topical Products
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Bioequivalence Studies Market, By Therapeutic Area
10.1. Bioequivalence Studies Market, by Therapeutic Area, 2022-2030
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Neurology
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Metabolic Disorders
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Hematology
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Immunology
10.1.5.1. Market Revenue and Forecast (2017-2030)
10.1.6. Orthopedics
10.1.6.1. Market Revenue and Forecast (2017-2030)
10.1.7. Others
10.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Bioequivalence Studies Market, By Phase
11.1. Bioequivalence Studies Market, by Phase, 2022-2030
11.1.1. Drug Discover
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Preclinical Studies
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Clinical Studies
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Bioequivalence Studies Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Type (2017-2030)
12.1.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.1.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.1.4. Market Revenue and Forecast, by Phase (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Phase (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Phase (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type (2017-2030)
12.2.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.2.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.2.4. Market Revenue and Forecast, by Phase (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Phase (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Phase (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Phase (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Phase (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type (2017-2030)
12.3.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.3.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.3.4. Market Revenue and Forecast, by Phase (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Phase (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Phase (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Phase (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Phase (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type (2017-2030)
12.4.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.4.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.4.4. Market Revenue and Forecast, by Phase (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Phase (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Phase (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Phase (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Phase (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type (2017-2030)
12.5.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.5.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.5.4. Market Revenue and Forecast, by Phase (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Phase (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Dosage Form (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Therapeutic Area (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Phase (2017-2030)
Chapter 13. Company Profiles
13.1. CliniExperts
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. ICBIO Corporation
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. ProRelix Services LLP
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. ICON plc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Charles River Laboratories International
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. PPD, Inc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Labcorp Drug Development
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. IQVIA
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Syneos Health
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. SGS SA
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers